NLS Pharmaceutics Ltd Stock

$1.82

2.15% day before yesterday

Nasdaq, Dec 27, 10:00 pm CET

ISIN

CH0523961370

Symbol

NLSP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

NLS Pharmaceutics Ltd Stock price

$1.82

-113.78 98.43% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.04 2.15%

ISIN

CH0523961370

Symbol

NLSP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$4.50m
Enterprise Value	$5.66m
P/E (TTM) P/E ratio	negative
P/B ratio (TTM) P/B ratio	negative
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-6.31m
EPS (TTM) EPS	$-0.19
P/E forward	negative
Short interest	4.36%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

NLS Pharmaceutics Ltd Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast NLS Pharmaceutics Ltd:

1x Hold

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast NLS Pharmaceutics Ltd:

Hold

100%

Analyst Estimates with Stock Price Targets

Financial data from NLS Pharmaceutics Ltd

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.01 0.01	0% 0% -
Gross Profit	-0.01 -0.01	0% 0% -
- Selling and Administrative Expenses	4.49 4.49	31% 31% -
- Research and Development Expense	1.80 1.80	77% 77% -
EBITDA	-6.30 -6.30	56% 56% -
- Depreciation and Amortization	0.01 0.01	0% 0% -
EBIT (Operating Income) EBIT	-6.31 -6.31	56% 56% -
Net Profit	-6.60 -6.60	57% 57% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

NLS Pharmaceutics Ltd Stock News

Neutral

Accesswire

●

10 days ago

NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment

This submission comes after successful INTERACT meeting with the FDA earlier this year. NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025 ZURICH, SWITZERLAND AND NESS ZIONA, ISRAEL / ACCESSWIRE / December 19, 2024 / NLS Pharmaceutics Ltd.

Neutral

Accesswire

●

18 days ago

NLS Pharmaceutics CEO Issues Letter to Shareholders

ZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced that its Chief Executive Officer, Alex Zwyer, has issued the follo...

Neutral

PRNewsWire

●

24 days ago

NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market

ZURICH , Dec. 4, 2024 /PRNewswire/ -- NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced the pricing of a private placement offering consisting of the issuance and sale ...

More NLS Pharmaceutics Ltd News

Company Profile

NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder(ADHD). The company was founded by Ronald Hafner and Alexander Zwyer in August 2015 and is headquartered in Stans, Switzerland.

Head office	Switzerland
CEO	Alexander Zwyer
Employees	4
Founded	2015
Website	www.nlspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now